Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

Event · M&A · completed
Role
acquirer
Counterparty
SOD Sciences, Inc.
Seller
SOD Sciences
Deal value
$12 million
Consideration
stock
Also in this documentOffering · 12KListing notice · regained compliance

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 19, 2026, 8:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$VVOS
Bullish
high confidence
Mentioned
$VVOS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VVOSBullishHigh
01

Why it matters

The deal adds >$10 M to equity, potentially restoring Nasdaq compliance and expanding market opportunity, but introduces convertible preferred shares that may dilute existing shareholders.

02

Market read

A material M&A transaction for a micro‑cap biotech, likely to move VVOS price as it addresses a listing compliance issue and expands its addressable market.

03

What to watch

Final approval of the AHA channel depends on bankruptcy court consent; delays could diminish the projected revenue upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Vivos Therapeutics (VVOS) filed an 8‑K announcing the closure of its acquisition of an equity stake in SOD Sciences and a co‑ownership of a pseudohypoxia early‑warning test, aiming to expand its patient reach and address Nasdaq equity‑requirement concerns.

Company-level read

Ticker impact

$VVOSBullishHigh confidence
Context

Vivos Therapeutics disclosed closing its acquisition of an 11% stake in SOD Sciences and a 50% interest in a pseudohypoxia test, adding >$10 M to stockholders’ equity and addressing Nasdaq listing requirements.

Expected impact

likely modest upside as the equity infusion supports compliance and growth prospects, tempered by dilution concerns

Evidence & confidence

First‑report 8‑K filing with concrete $10 M equity addition; market typically reacts positively to compliance‑related capital infusions for micro‑caps.

Market effects

May signal increased M&A activity in the sleep‑apnea and diagnostic‑test niche, prompting peers to reassess partnership strategies.

Limited to U.S. micro‑cap and Nasdaq‑listed biotech space.

Low; impact confined to Vivos and its immediate partners.

Counterpoint

The convertible preferred issuance could lead to future dilution and voting power shifts, potentially pressuring the stock if performance expectations are not met.

Key entities

  • Vivos Therapeutics, Inc.

    Nasdaq‑listed developer of sleep‑apnea therapies.

  • SOD Sciences, Inc.

    Provider of the pseudohypoxia early‑warning test.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$DASHHighAI 9/10

DoJ To Reportedly Scrutinize DoorDash And Instacart’s $17B Merger

The U.S. Department of Justice will review DoorDash's proposed $17 billion acquisition of Instacart, valued at $65 per share, according to Reuters. The deal aims to expand DoorDash's presence in the U.S. online grocery market. DASH stock rose 0.7% after-hours, while CART stock fell $2. The transaction is expected to close by late 2027 or early 2028, pending regulatory approval.

$TUMedAI 8/10

What you need to know about a proposed Quebecor-Telus merger

Quebecor Inc. proposed a $31-billion merger with Telus, raising concerns about competition and regulatory approval. Analysts suggest the deal could reduce wireless competition, potentially increasing prices. Telus's stock has declined 32% year-to-date, making it an attractive target. The merger could face regulatory hurdles, including potential asset spin-offs.